MedTrace Logo

Establishment of a Tissue Bank (Blood, CSF) for the Understanding of Motor Neuron Disease (MND)

NCT01950910 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 766

Last updated 2022-07-11

No results posted yet for this study

Summary

Biomarkers are essential for the identification of disease states. There are no early diagnostic or prognostic markers for ALS. The purpose of this study is to identify a panel of biomarkers from blood or spinal fluid of ALS patients and to collect data to better understand disease progression.

Conditions

Sponsors & Collaborators

  • Wake Forest University Health Sciences

    lead OTHER

Principal Investigators

  • Benjamin R Brooks, MD · Neurosciences Institute, Neurology - Charlotte

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-03-29
Primary Completion
2017-12-31
Completion
2020-10-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01950910 on ClinicalTrials.gov